Propanc Biopharma Files 8-K on Agreements and Equity Sales
Ticker: PPCB · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $20,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, equity-sale
TL;DR
Propanc Biopharma dropped an 8-K detailing new agreements, financial obligations, and equity sales.
AI Summary
On June 3, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement related to its financial obligations. The company also reported on the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Additionally, Propanc Biopharma disclosed unregistered sales of equity securities and filed financial statements and exhibits.
Why It Matters
This filing indicates significant financial and corporate actions by Propanc Biopharma, including new agreements and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, which can carry inherent risks related to financial commitments and share dilution.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- June 3, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 000-54878 (filing_id) — SEC File Number
- 33-0662986 (tax_id) — IRS Employer Identification Number
FAQ
What type of material definitive agreement did Propanc Biopharma, Inc. enter into?
The filing indicates Propanc Biopharma, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in this summary.
What are the key items reported in this 8-K filing?
The key items reported are the entry into a material definitive agreement, creation of a direct financial obligation or off-balance sheet arrangement, unregistered sales of equity securities, and financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 3, 2024.
What is Propanc Biopharma, Inc.'s state of incorporation?
Propanc Biopharma, Inc. is incorporated in Delaware.
What is the SEC file number for Propanc Biopharma, Inc.?
The SEC file number for Propanc Biopharma, Inc. is 000-54878.
Filing Stats: 755 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2024-06-12 06:01:19
Key Financial Figures
- $20,000 — ompany an aggregate principal amount of $20,000 AUD. The Company intends to use the net
- $100,000 — ompany an aggregate principal amount of $100,000 AUD. The Company intends to use the net
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex4-1.htm (EX-4.1) — 12KB
- ex4-2.htm (EX-4.2) — 13KB
- ex4-1_001.jpg (GRAPHIC) — 12KB
- ex4-1_002.jpg (GRAPHIC) — 13KB
- ex4-1_003.jpg (GRAPHIC) — 5KB
- ex4-1_004.jpg (GRAPHIC) — 7KB
- ex4-2_004.jpg (GRAPHIC) — 12KB
- ex4-2_001.jpg (GRAPHIC) — 8KB
- ex4-2_002.jpg (GRAPHIC) — 6KB
- ex4-2_003.jpg (GRAPHIC) — 5KB
- 0001493152-24-023525.txt ( ) — 329KB
- ppcb-20240603.xsd (EX-101.SCH) — 3KB
- ppcb-20240603_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240603_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 11, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer